Blocking IL‐33 signaling reduces polyp growth, increases apoptosis, and inhibits angiogenesis in ApcMin/+ mice, thereby showing the potential of IL‐33 as a therapeutic target in CRC [234]. This evidence concerns the gene IL33 and colorectal carcinoma.